2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Treatment Considerations, Combination Therapy, Drug Development, Non-Biological Therapies, Chemotherapy, Pharmacology, Adverse Events, Clinical Practice (Health Services and Quality), Patient Safety, Diseases, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, Research, AML, APL, Translational Research, MDS, Clinical Research, Clinical Trials, Health Outcomes Research, Real-World Evidence, Survivorship, Study Population, Human, Adult, Elderly, Young Adult
PAPER

5180 Venetoclax plus all-trans-retinoic acid as induction therapy in newly diagnosed adult acute promyelocytic leukemia: Early safety and efficacy findings

Xuechun Wang, MD, Qian Ding2, Jinqiong Li, MD3, Xiao Han4, Zhang Mengyun5, Jincheng Gao, MD6, Cheng Zhang, MD7, Wen Qin, MD8, Xi Zhang, MD9
1 Xinqiao Hospital of Army Medical University, Chongqing, China
2 The People's Hospital of Guizhou Province, Guiyang, China
3 Lijiang People's Hospital, Yunnan, China
4 Xinqiao Hospital of Army Medical University, Chongqing, China
5 Xinqiao Hospital of Army Medical University, Chongqing, China
6 Xinqiao Hospital of Army Medical University, Chongqing, China
7 Xinqiao Hospital of Army Medical University, Chongqing, China
8 Xinqiao Hospital of Army Medical University, Chongqing, China
9 Xinqiao Hospital of Army Medical University, Chongqing, China
Background: Acute promyelocytic leukemia (APL) achieves high cure rates with ATRA+ATO (all-trans retinoic acid + Arsenic Trioxide), yet early mortality remains 8-15% due to coagulopathy and differentiation syndrome (DS). ATO application brings significant toxicities, even fatal complications. Venetoclax (VEN), a BCL-2 inhibitor, shows favorable safety and efficacy in AML and emerging APL reports. Therefore, this study evaluates whether VEN+ATRA can provide a safe, effective induction strategy for newly diagnosed adult APL.

Methods: Adult patients with newly diagnosed APL received VEN+ATRA induction (for WBC ≥4×10?/L, VEN 100?mg qd is given until WBC <4×10?/L; for WBC <4×10?/L, VEN 100?mg qd plus ATRA 25?mg/m²/day for 28?days in total). Assessments include Disseminated Intravascular Coagulation (DIC) and hematologic recovery, transfusion requirements, and adverse events (AE) related to early mortality. Post-induction evaluation includes bone marrow (BM) blast clearance and PML::RARα expression.

Results: From February 10 to July 22, 2026, 18 eligible patients received VEN+ATRA induction. The mean age was 49.2 years (25-70), with 11 males and 7 females. Baseline laboratory values showed a mean WBC 9.7×10?/L (105.6-0.51) and PLT 40.8×10?/L (124-4). Per the 2018 Chinese APL guideline, 2 patients were high-risk (high), 11 intermediate-risk (inter), and 5 low-risk (low). 1. VEN+ATRA induced rapid correction of coagulopathy. 15/17 evaluable patients presented with DIC (CDSS Chinese DIC Scoring System, CDSS ≥ 6). The mean time to coagulation improvement (CDSS ≤ 5) was 6.3 days (low 3.6; inter 6.4; high 10). PT normalization (<15.5s) was achieved within 3-4 days, and 11/18 patients showed no upward trend in PT after treatment initiation, indicating early stabilization of coagulation parameters. 2. VEN+ATRA showed low transfusion requirements. 10/18 patients received plasma (mean 280?mL, range 0-850). 11/18 received cryoprecipitate (mean 7.8?U, range 0-26). 10/18 required fibrinogen supplementation (mean 3.5?g, range 0-22). 9/18 received RBC transfusion (mean 2.25 U). 10/18 required platelet transfusion (mean 2.4 therapeutic doses); notably, no platelet transfusion was needed in low-risk APL. 3. VEN+ATRA shortened hematologic recovery time and length of stay (LOS). Platelet recovery occurred at a mean of 10.8 days (4-26) (low 6.8; inter 10.5; high 22). Hemoglobin recovery averaged 13.9 days (5-33) (low 7; inter 13.1; high 28). ANC (absolute neutrophil count) recovery occurred at 16.9 days (low 14.7; inter 16.4; high 22.5). Mean LOS was 13 days (5-32) (low 9.2; inter 12.2; high 26.5), indicating faster clinical stabilization. 4. VEN+ATRA demonstrated a favorable safety profile. Five patients required antibiotic therapy for infection management; three received voriconazole for empiric treatment, and two received posaconazole prophylaxis. No infectious shock occurred. Except for one high-risk patient (WBC 105.6×10?/L) who received prednisone prophylaxis for DS, no corticosteroids were used in the 17 patients. No DS, hemorrhagic events, Tumor Lysis Syndrome (TLS), hepatic/renal failure, or deaths occurred during induction. 5. VEN+ATRA demonstrated promising therapeutic efficacy. Among 13/18 patients who underwent NGS, WT1 mutations were found in 3, NRAS in 2, ETV6 in 1, FLT3-ITD in 1, and FLT3-TKD in 1 patient. Mean BM blasts decreased from 78.1% at D0 (43-96%) to 16% at D14 (0-68%) and 1% at D28 (0-2.8%). Blast clearance occurred in 4/13 patients by D14 and 6/14 by D28. For PML::RARα, 14 patients underwent quantitative testing and 4 qualitative tests. Mean transcript levels declined from 40.48% at D0 (16.5-79%) to 31.16% at D14 (5.4-70.4%) and 1.446% at D28 (0-15.7%, median 0.068%). Molecular remission (0%) was achieved in 2/12 evaluable patients by D28.

Conclusions: Our findings demonstrate that the VEN+ATRA regimen achieved rapid correction of coagulopathy, low transfusion requirements, and accelerated hematologic recovery, leading to shorter hospitalization and a favorable safety profile without severe adverse events during induction. By day 28, both BM blast burden and PML::RARα transcript levels declined markedly, demonstrating a clear early molecular response. Although larger cohorts, longer follow-up, and randomized controlled studies are needed, VEN+ATRA may represent a safe and effective induction strategy for newly diagnosed adult APL.
Xuechun Wang, MD: No relevant conflicts of interest to declare.